Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trientine and Vemurafenib in BRAF-mutated Metastatic Melanoma
NCT02068079Phase 1Withdrawn
- Sponsor
- Duke University
- Start
- Apr 2014
- Primary completion
- Nov 2015
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trientine in melanoma, sponsored by Duke University. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Planned start Apr 2014; status: withdrawn.
02
Drugs
trientine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02068079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068079.